JUN 18, 2019 8:19 AM PDT

Scientists Identify Which Gut Bacteria Interfere With Parkinson's Treatment

WRITTEN BY: Tiffany Dazet

A new study from a team of Harvard scientists discovered one of the first distinct examples of how gut bacteria can interfere with a drug’s pathway through the body. Out of the trillions of possible culprits, the team was able to identify which bacteria degrade the drug and how to stop the interference.

The study, recently published in Science, focused on levodopa (L-dopa), which has been the primary treatment for Parkinson’s disease for the past 50 years. L-dopa relieves Parkinson’s symptoms by delivering dopamine to the brain. However, it is estimated that only about one to five percent of the drug actually reaches the brain.

When the L-dopa metabolizes outside the brain, the resulting dopamine causes side effects, including severe gastrointestinal distress and cardiac arrhythmias. In addition, patients are often given higher doses of the drug to combat symptoms, possibly intensifying these side effects. 

To increase the efficacy of L-dopa, a new drug to block the L-dopa metabolism—carbidopa—was introduced, and the combination of the pills seemed to help Parkinson’s patients. Although this solution exists, the research team wanted to dig deeper and discover the unexplained drug metabolism and reasons for efficacy variance between patients.

Using data from the Human Microbiome Project, the team was able to identify specific enzymes produced by two different bacterial species that work together to digest L-dopa in the human gut. Enterococcus faecalis absorbs L-dopa and converts it to dopamine while Eggerthella lenta converts dopamine into meta-tyramine, which may be responsible for L-dopa’s side effects.

In a statement from Harvard’s Department of Chemistry and Chemical Biology, lead author Professor Emily Balskus stated that “all of this suggests that gut microbes may contribute to the dramatic variability that is observed in side effects and efficacy between different patients taking L-dopa.”

Using mice, the research team also identified a small molecule—alpha-fluoromethyltyrosine (AFMT)—that could block this particular metabolic pathway, thereby increasing the efficacy of L-dopa in Parkinson’s patients. Although this may result in Parkinson’s patients requiring a third drug for treatment, Balskus stated that their discovery “opens up the door to the possibility of developing a new class of therapeutics to improve patient response to L-dopa—that would be drugs targeting gut microbe metabolism in addition to targeting host metabolism.”

Sources: Harvard, Science Magazine, New Scientist

About the Author
  • Tiffany grew up in Southern California, where she attended San Diego State University. She graduated with a degree in Biology with a marine emphasis, thanks to her love of the ocean and wildlife. With 13 years of science writing under her belt, she now works as a freelance writer in the Pacific Northwest.
You May Also Like
JAN 16, 2020
Chemistry & Physics
JAN 16, 2020
Self-healable Sweat Sensor Fears No Wear and Tear
Sweat can provide a lot of information about a person's health. One of the current trends in wearable technology is to incorporate sweat sensing mechan...
JAN 17, 2020
Genetics & Genomics
JAN 17, 2020
Soybean Oil Found to Change Gene Expression in the Brain
Soybean oil is used for frying and for making foods like margarine and salad dressing. It's the most commonly produced and consumed edible oil in the US....
JAN 20, 2020
Genetics & Genomics
JAN 20, 2020
Epigenetic Changes Make Breast Cancer Cells Drug Resistant
Researchers have found that changes in the structure of the genome in breast cancer cells can make them resistant to drug therapies....
JAN 31, 2020
Microbiology
JAN 31, 2020
Wuhan Coronavirus: WHO Declares Global Emergency
Since the first cases of a novel Coronavirus were detected in Wuhan, China a few weeks ago, the virus has spread around the globe....
FEB 08, 2020
Microbiology
FEB 08, 2020
Novel Coronavirus Has Now Infected At Least 34,500 People
In China, authorities are still struggling to contain the new coronavirus that emerged in the city of Wuhan and has since spread around the globe....
FEB 17, 2020
Immunology
FEB 17, 2020
Another HIV vaccine attempt fizzles out
Years of work and over $100 million in study costs have been abandoned after an HIV-vaccine tested in South Africa failed to protect treated individuals ag...
Loading Comments...